Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Therapeutic Class
1.1.2. Treatment
1.1.3. End-use
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Therapeutic class outlook
2.2.2. Treatment outlook
2.2.3. End-use outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Ovarian Cancer Drugs Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Ovarian Cancer Drugs Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Ovarian Cancer Drugs: Therapeutic Class Estimates & Trend Analysis
4.1. Ovarian Cancer Drugs Market: Key Takeaways
4.2. Ovarian Cancer Drugs Market: Movement & Market Share Analysis, 2022 & 2030
4.3. PARP Inhibitors
4.3.1. PARP inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Angiogenesis inhibitors
4.4.1. Angiogenesis inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. PD-L1 inhibitors
4.5.1. PD-L1 inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Ovarian Cancer Drugs: End-use Estimates & Trend Analysis
5.1. Ovarian Cancer Drugs Market: Key Takeaways
5.2. Ovarian Cancer Drugs Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Hospital Pharmacy
5.3.1. Hospital pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Retail pharmacy
5.4.1. Retail pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Online Pharmacy
5.5.1. Online pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Ovarian Cancer Drugs: Treatment Estimates & Trend Analysis
6.1. Ovarian Cancer Drugs Market: Key Takeaways
6.2. Ovarian Cancer Drugs Market: Movement & Market Share Analysis, 2022 & 2030
6.3. Chemotherapy
6.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Radiation Therapy
6.4.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Hormonal Therapy
6.5.1. Hormonal therapy market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Targeted Therapy & others
6.6.1. Targeted therapy & others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Ovarian Cancer Drugs Market: Regional Estimates & Trend Analysis
7.1. Regional Outlook
7.2. Ovarian Cancer Drugs Market by Region: Key Takeaway
7.3. North America
7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.3.2. U.S.
7.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.3.3. Canada
7.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.2. Germany
7.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.3. France
7.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.4. Italy
7.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.5. Spain
7.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.6. Sweden
7.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.7. Norway
7.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.8. Denmark
7.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.2. China
7.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.3. India
7.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.4. Australia
7.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.5. Thailand
7.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.6. South Korea
7.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.6.2. Mexico
7.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.6.3. Argentina
7.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7. MEA
7.7.1. Saudi Arabia
7.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7.2. South Africa
7.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7.3. UAE
7.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7.4. Kuwait
7.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Market Participant Categorization
8.2.1. AbbVie Inc.
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Product benchmarking
8.2.1.4. Strategic initiatives
8.2.2. Pfizer, Inc.,
8.2.2.1. Company overview
8.2.2.2. Financial performance
8.2.2.3. Product benchmarking
8.2.2.4. Strategic initiatives
8.2.3. AstraZeneca,
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Product benchmarking
8.2.3.4. Strategic initiatives
8.2.4. F. Hoffmann-La Roche AG,
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Product benchmarking
8.2.4.4. Strategic initiatives
8.2.5. Johnson & Johnson Services, Inc.,
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Product benchmarking
8.2.5.4. Strategic initiatives
8.2.6. Boehringer Ingelheim International GmbH,
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Product benchmarking
8.2.6.4. Strategic initiatives
8.2.7. Clovis Oncology,
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Product benchmarking
8.2.7.4. Strategic initiatives
8.2.8. ImmunoGen, Inc.
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Product benchmarking
8.2.8.4. Strategic initiatives
8.2.9. Vivesto AB
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Product benchmarking
8.2.9.4. Strategic initiatives